JP2023518340A5 - - Google Patents
Info
- Publication number
- JP2023518340A5 JP2023518340A5 JP2022548838A JP2022548838A JP2023518340A5 JP 2023518340 A5 JP2023518340 A5 JP 2023518340A5 JP 2022548838 A JP2022548838 A JP 2022548838A JP 2022548838 A JP2022548838 A JP 2022548838A JP 2023518340 A5 JP2023518340 A5 JP 2023518340A5
- Authority
- JP
- Japan
- Prior art keywords
- combination according
- combination
- antigen
- mrna molecules
- mrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20157300 | 2020-02-14 | ||
| EP20157300.3 | 2020-02-14 | ||
| PCT/EP2021/053633 WO2021160881A1 (en) | 2020-02-14 | 2021-02-15 | Intranasal mrna vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023518340A JP2023518340A (ja) | 2023-05-01 |
| JP2023518340A5 true JP2023518340A5 (https=) | 2024-01-25 |
Family
ID=69593570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548838A Pending JP2023518340A (ja) | 2020-02-14 | 2021-02-15 | 鼻腔内ｍＲＮＡワクチン |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230071518A1 (https=) |
| EP (1) | EP4103226A1 (https=) |
| JP (1) | JP2023518340A (https=) |
| KR (1) | KR20230004447A (https=) |
| CN (1) | CN115443148B (https=) |
| AU (1) | AU2021219304A1 (https=) |
| BR (1) | BR112022015666A2 (https=) |
| CA (1) | CA3170239A1 (https=) |
| IL (1) | IL295507A (https=) |
| MX (1) | MX2022009943A (https=) |
| TW (1) | TW202144002A (https=) |
| WO (1) | WO2021160881A1 (https=) |
| ZA (1) | ZA202209779B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11814464B2 (en) | 2019-04-29 | 2023-11-14 | Yale University | Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| AU2021293780A1 (en) | 2020-06-19 | 2023-02-02 | Yale University | Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery |
| US11918643B2 (en) | 2020-12-22 | 2024-03-05 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
| WO2023037320A1 (en) * | 2021-09-10 | 2023-03-16 | Intron Biotechnology, Inc. | Mucosal messenger rna vaccine |
| JP2024545093A (ja) * | 2021-12-08 | 2024-12-05 | イェール ユニバーシティー | 細胞および組織に標的化するためのポリ（アミン－ｃｏ－エステル）ナノ粒子への表面コンジュゲーション |
| EP4608442A1 (en) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Nucleic acid based vaccine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130108663A1 (en) * | 2007-09-14 | 2013-05-02 | Vrije Universiteit Brussel | Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination |
| HUE058792T2 (hu) * | 2013-11-12 | 2022-09-28 | Univ Brussel Vrije | RNS-transzkripciós vektor és felhasználása |
| PL4023249T3 (pl) * | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| EP4011451A1 (en) * | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| CA3040337A1 (en) * | 2016-10-26 | 2018-05-03 | Curevac Ag | Lipid nanoparticle mrna vaccines |
| CA3088485A1 (en) * | 2018-01-18 | 2019-07-25 | Etherna Immunotherapies Nv | Lipid nanoparticles |
-
2021
- 2021-02-15 MX MX2022009943A patent/MX2022009943A/es unknown
- 2021-02-15 IL IL295507A patent/IL295507A/en unknown
- 2021-02-15 KR KR1020227031704A patent/KR20230004447A/ko active Pending
- 2021-02-15 BR BR112022015666A patent/BR112022015666A2/pt not_active IP Right Cessation
- 2021-02-15 CA CA3170239A patent/CA3170239A1/en active Pending
- 2021-02-15 WO PCT/EP2021/053633 patent/WO2021160881A1/en not_active Ceased
- 2021-02-15 JP JP2022548838A patent/JP2023518340A/ja active Pending
- 2021-02-15 EP EP21705192.9A patent/EP4103226A1/en not_active Withdrawn
- 2021-02-15 AU AU2021219304A patent/AU2021219304A1/en not_active Abandoned
- 2021-02-15 CN CN202180009112.1A patent/CN115443148B/zh not_active Expired - Fee Related
- 2021-02-15 US US17/799,118 patent/US20230071518A1/en not_active Abandoned
- 2021-02-17 TW TW110105299A patent/TW202144002A/zh unknown
-
2022
- 2022-09-01 ZA ZA2022/09779A patent/ZA202209779B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023518340A5 (https=) | ||
| Akbari et al. | Potential therapeutic application of mesenchymal stem cell-derived exosomes in SARS-CoV-2 pneumonia | |
| US20230381301A1 (en) | Respiratory virus nucleic acid vaccines | |
| JP2010516290A5 (https=) | ||
| US20230084300A1 (en) | Prevention and treatment of infections including those caused by coronavirus | |
| US20220280635A1 (en) | Particles for stimulating an immune response against viral infections | |
| JP2003518507A5 (https=) | ||
| Tian et al. | mRNA vaccines: A novel weapon to control infectious diseases | |
| CN112552379B (zh) | 合成肽在制备防治新型冠状病毒感染药物中的用途 | |
| Mohapatra | Mucosal gene expression vaccine: a novel vaccine strategy for respiratory syncytial virus | |
| US12409149B2 (en) | Methods of targeted delivery to a host using a carrier | |
| Damodharan et al. | A comprehensive overview of vaccines developed for pandemic viral pathogens over the past two decades including those in clinical trials for the current novel SARS-CoV-2 | |
| F Nahhas et al. | Nanoscale pathogens treated with nanomaterial-like peptides: a platform technology appropriate for future pandemics | |
| Duman et al. | COVID-19 vaccine candidates and vaccine development platforms available worldwide | |
| Shah et al. | A Review on Modern Use of Intranasal Vaccination in the Treatment of SARS-COV-2. | |
| JP2022513438A5 (https=) | ||
| CN113185586B (zh) | SARS-CoV-2编码蛋白来源的T细胞表位多肽及其应用 | |
| CN102827248B (zh) | 一种具有抗日本脑炎病毒感染的三肽及其应用 | |
| JP2023526045A5 (https=) | ||
| Lutz et al. | Advanced nanobiomedical approaches to combat coronavirus disease of 2019 | |
| WO2023280303A1 (zh) | Avc-29作为疫苗佐剂的用途以及含有该佐剂的疫苗组合物 | |
| Robertson et al. | International Nonproprietary Names (INN) for novel vaccine substances: a matter of safety | |
| Singh et al. | Current Insights on Vaccines available for COVID-19 like Flu Symptoms | |
| Zhai et al. | Dongmei Y. Knowledge Distillation for COVID-19 Therapeutics | |
| Shah et al. | A Review on Current COVID-19 Vaccines and Evaluation of Particulate Vaccine Delivery Systems. Vaccines 2021, 9, 1086 |